Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

Journal Article (Clinical Trial, Phase III;Journal Article;Multicenter Study)

To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer > or =40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.

Full Text

Duke Authors

Cited Authors

  • Talbot, HK; Keitel, W; Cate, TR; Treanor, J; Campbell, J; Brady, RC; Graham, I; Dekker, CL; Ho, D; Winokur, P; Walter, E; Bennet, J; Formica, N; Hartel, G; Skeljo, M; Edwards, KM

Published Date

  • July 29, 2008

Published In

Volume / Issue

  • 26 / 32

Start / End Page

  • 4057 - 4061

PubMed ID

  • 18602726

Pubmed Central ID

  • PMC2605420

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2008.05.024


  • eng

Conference Location

  • Netherlands